Brain scans may unlock why antipsychotics work for some, not others

NCT ID NCT03442101

Ongoing Knowledge-focused Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 156 people experiencing their first episode of psychosis who have never taken antipsychotic medication. Participants receive standard treatment with risperidone or aripiprazole and undergo brain scans four times over 32 weeks. The goal is to identify brain differences that predict who will respond well to treatment, which could lead to more personalized care and new therapies for those who don't improve.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: risperidone and aripiprazole (antipsychotic medications)
What this could lead to: If successful, this could help doctors predict which patients will respond to standard antipsychotics and point toward new treatments for those who don't.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly improve care. The findings may not apply to all patients with psychosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSYCHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psychotic disorder Psychotic Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSYCHOSIS

Contacts and locations

Locations

Sparks Center

Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.